The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma

• Published in: World journal of surgery Vol. 43; no. 8; pp. 2006 - 2015
• Main Authors: Takeuchi, Masashi, Kawakubo, Hirofumi, Mayanagi, Shuhei, Yoshida, Kayo, Irino, Tomoyuki, Fukuda, Kazumasa, Nakamura, Rieko, Wada, Norihito, Takeuchi, Hiroya, Kitagawa, Yuko
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 15.08.2019; Springer Nature B.V
• Subjects: 5-Fluorouracil; Abdominal Surgery; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer; Cancer therapies; Cardiac Surgery; Chemoradiotherapy; Chemotherapy; Chemotherapy, Adjuvant; Cisplatin; Cisplatin - administration & dosage; Docetaxel - administration & dosage; Esophageal cancer; Esophageal Neoplasms - pathology; Esophageal Neoplasms - therapy; Esophageal Squamous Cell Carcinoma - secondary; Esophageal Squamous Cell Carcinoma - therapy; Esophagectomy; Esophagus; Feasibility studies; Female; Fistulae; Fluorouracil - administration & dosage; General Surgery; Humans; Induction Chemotherapy - methods; Induction therapy; Male; Medical prognosis; Medicine; Medicine & Public Health; Metastases; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Second Primary; Original Scientific Report; Patients; Perforation; Progression-Free Survival; Squamous cell carcinoma; Stricture; Surgery; Survival; Thoracic Surgery; Vascular Surgery
• ISSN: 0364-2313; 1432-2323
• DOI: 10.1007/s00268-019-05000-3

Background Definitive chemoradiotherapy (CRT), used for treatment of patients with an initial diagnosis of unresectable locally advanced esophageal cancer, has led to unsatisfactory long-term prognosis. Moreover, CRT can lead to esophageal fistula, perforation, and strictures. Therefore, strong induction chemotherapeutic treatments are necessary to reduce the tumor volume for subsequent radical esophagectomy. This study aimed to determine the oncological utility of docetaxel plus cisplatin and 5-fluorouracil (DCF) and the technical feasibility of subsequent esophagectomy for locally advanced esophageal cancer. Methods Eighty-seven patients with clinical borderline unresectable T3 and T4 esophageal squamous cell carcinoma without distant metastases were included in this study. There were 44 patients in primary DCF group and 43 patients in definitive CRT group, and perioperative and long-term oncological outcomes were compared between the two groups. Results Twenty-two patients (50%) achieved R0 resection in the DCF group. Albeit not significant, the rate of curative treatment was higher in the DCF group than the definitive CRT group ( p  = 0.099). The overall survival (OS) and progression-free survival (PFS) were better with DCF than with definitive CRT (median OS, 29 vs. 17 months, p  = 0.206; median PFS, 10 vs. 6 months, p  = 0.020). Specifically, the OS of patients with a Charlson score of less than 3 among the DCF-treated patients tended to be better than those among the definitive CRT-treated patients. Conclusion DCF and subsequent esophagectomy achieved R0 resection in 50% of the patients and was associated with better long-term oncological outcomes in patients with initially unresectable esophageal cancer if their systemic status is acceptable.